A health system pilots an AI tool. Clinicians like it, the early numbers look good, and six months later it is still not in production. The model is rarely the reason. What stops a healthcare AI pilot to production is a short list of gates that nobody planned for, and each one belongs to a different department.

This guide covers those gates in the order a buyer meets them: the security review, the EHR integration, the measurement of results, and the question of who owns the product once the project team leaves. It is written for the executive who has a pilot that worked and a rollout that has not started.

It picks up where our guide to AI-assisted MVP development stops, with a first version built and a buyer asking what happens next.

Why Do Healthcare AI Pilots Stall Before Production?

Healthcare AI pilots stall because pilot conditions, a narrow scope, borrowed data and one champion's goodwill, do not survive enterprise conditions, which add a security review, EHR integration, measured outcomes and a named owner.

Pilot to production, also described as the prototype to production gap, means moving a tool from a controlled trial to live, supported use inside the organization's own systems and under its own policies. Pilot purgatory is what happens when that move never gets decided. The pilot keeps running, or keeps being renewed, with no decision to scale it or stop it.

In practice five things cause it:

1. Nobody holds the mandate. The pilot has a sponsor but no one with authority and budget to scale it.
2. The security review arrives late. It is treated as paperwork after the pilot, when it is the first real test of the vendor.
3. Integration was scoped from a demo. A tool that runs beside the EHR is a different project from one that runs inside the clinical workflow.
4. There is no agreed measure of success. Without a threshold to scale and a threshold to stop, every result can be argued either way.
5. No one is funded to run it afterward. Support, monitoring and change management have no owner and no line in the budget.

The statistic quoted most often is that 95% of enterprise AI pilots fail. It is narrower than the headline suggests. The MIT Project NANDA report behind it describes 5% of custom or vendor-sold enterprise AI tools reaching production, judged against a test of marked and sustained productivity or profit impact. It draws on 52 interviews, 153 survey responses and a review of more than 300 public initiatives, collected from January to June 2025, and it labels its findings preliminary. It is a cross-industry signal that scaling is hard, not a healthcare benchmark.

What Changes Between a Pilot and an Enterprise Deployment?

The same tool faces a different set of conditions on each side of the line. These are the seven differences that decide whether a pilot survives the move:

• Scope. A pilot covers one unit and one use case. Production covers many units on shared infrastructure.
• Data. A pilot often runs on extracts, synthetic records or a sponsor's data. Production runs on live patient data under a signed agreement.
• Users. A pilot is used by volunteers and the champion. Production is used by everyone, including the people who did not ask for it.
• Security. A pilot gets informal access. Production passes a formal review before access is granted.
• Integration. A pilot relies on a separate screen or a manual export. Production connects to the EHR, the identity system and monitoring.
• Support. A pilot is covered by the project team on call. Production needs a support process, an incident path and a plan for downtime.
• Accountability. A pilot rests on a sponsor's goodwill. Production needs a named owner and a budget line.

What Does a Health System Security Review Ask an AI Vendor For?

The review is a gate, and what it asks for is predictable. Preparing the answers before the pilot ends is the cheapest way to shorten it. Buyers often call it an AI vendor risk assessment, and for a HIPAA-covered organization it works as a HIPAA vendor risk assessment as well.

Start with the legal basis. Under 45 CFR 160.103, a vendor that creates, receives, maintains or transmits protected health information on a covered entity's behalf is a business associate. Under 45 CFR 164.502(e), the covered entity may allow that only with written satisfactory assurances. In plain terms, no real patient data should reach the tool, even in a pilot, until a business associate agreement is signed.

Buyer guidance such as the Censinet list of AI vendor risk questions shows what a review typically requests. Expect to produce:

• A signed business associate agreement that covers the whole data flow, not only the product's front end.
• A data flow diagram showing where patient data enters, where it is stored, where it leaves and which subprocessors touch it.
• Independent security reports such as SOC 2 Type II, HITRUST or ISO 27001, and a clear statement of whether they cover the AI components.
• Evidence of security testing and a list of every subprocessor with its role.

AI products draw a second set of questions that older software never faced:

• Training and validation. How the model was trained and tested, and how it performed across patient groups.
• Use of your data. Whether customer data is ever used to train or fine-tune a model, stated in writing and in the contract.
• Change and drift. How model updates are announced, versioned and revalidated, and how drift is monitored.
• Audit logs. A record of who acted, which model version ran and whether a clinician overrode the output.
• Human oversight. Who can override the system and who can shut it off.
• Regulatory status. Whether the software is a medical device and, if so, its actual status. The FDA states that registration and listing does not denote approval, clearance or authorization, so "FDA registered" is not an answer.

Prepare this packet once, keep it current, and name one person who owns the answers. Our guide to building HIPAA-compliant software covers the engineering controls behind these documents, and the same thinking runs through our compliance and data governance practices.

How Do You Integrate an AI Product With the EHR and Clinical Workflow?

A pilot can run beside the EHR to test whether an idea works. A production tool has to sit inside the work clinicians already do, or adoption stalls however good the model is. That is a separate project, and it cannot be scoped from a demo.

Most integrations use one of two routes: interfaces built on HL7 v2 messages, or APIs built on FHIR. For applications that launch inside the EHR, the HL7 SMART App Launch guide describes patterns based on OAuth 2.0 that let an application authorize, authenticate and integrate with FHIR-based systems. Which route fits depends on the EHR, the use case and what the buyer's integration team will support.

Settle six questions before the pilot ends:

1. Where does the AI output appear in the clinician's screen, and who sees it?
2. What, if anything, is written back to the record?
3. How do users sign in, and does access follow the organization's identity system?
4. What happens when the AI service is down or slow?
5. Who builds and maintains the interface, and who is called when it breaks?
6. How does performance hold when every eligible user is on the system at once?

The detail behind these answers is the work of healthcare integration, interoperability and SMART on FHIR engineering. Treat it as its own workstream, with its own owner, from the first week.

How Should You Measure a Healthcare AI Pilot So It Can Scale?

Most advice says to measure the pilot. Few say how. Four decisions made before the build starts turn a pilot into evidence:

1. A baseline. Record how the work is done today, in minutes, errors or cost, before the tool is switched on.
2. A threshold to scale. Agree in writing what result justifies a wider rollout.
3. A threshold to stop. Agree what result ends the pilot, so that no result can be argued into another renewal.
4. A fixed window. Set the end date at the start.

Then choose measures from five families:

• Operational. Minutes per task, turnaround time, backlog.
• Quality. Error rate, rework, and how often staff override the output.
• Safety. Incidents, escalations and near misses linked to the tool.
• Adoption. The share of eligible users who use it each week, and who has stopped.
• Cost per use. The full cost of running the tool divided by the tasks it completed.

A worked example in words: for a tool that drafts prior authorization requests, the baseline is the minutes staff spend per request today. The scale threshold is a stated reduction in those minutes with no rise in denials. The stop threshold is no meaningful reduction by the end of the window. Every number is agreed with the finance and clinical owners before the first request is drafted.

Who Needs to Own an AI Product After the Pilot?

A pilot can run on enthusiasm. A production system needs five named owners, each with a defined job:

1. Executive sponsor. Holds the mandate and the budget, and clears obstacles between departments.
2. Clinical owner. Answers for safety, workflow fit and the use of the output in care.
3. IT owner. Answers for integration, support and uptime.
4. Security owner. Answers for the review, the evidence and each model or vendor change.
5. Product owner. Runs the roadmap, the vendor relationship and the measures from the previous section.

In healthcare software implementation, adoption follows ownership. Clinicians use tools that fit their work and that someone will fix when they break, so training, a support route and a feedback loop belong in the plan from the start.

Health system leaders describe the same pattern. In an HCI Innovation Group interview, a Baylor Scott & White Health information systems executive and a managing director at a healthcare consulting firm discuss two habits. One is asking how a pilot would scale before it starts. The other is vetting whether a vendor is viable. A vendor that can show a named owner and a support plan answers both questions at once.

What Does an Enterprise-Ready Build Look Like From Day One?

The evidence a buyer asks for is far cheaper to produce while the product is being built than to reconstruct afterward. Seven things should exist before the pilot ends:

• Separate environments. Development, test and production kept apart, with no real patient data in the first two.
• A review gate on every change. A named engineer approves each change before it merges, with a second reviewer where patient data or access control is touched.
• Audit logging. Records of who did what, and which model version produced each output.
• An evaluation harness. A fixed test set run on every model or prompt change, so a regression is caught before a clinician sees it.
• Monitoring and drift alerts. Dashboards for accuracy, latency, cost and override rates, with owners for each alert.
• Rollback and version records. The ability to return to the last known good version, and a registry of what ran when.
• Cost and usage controls. Limits that stop a successful pilot from becoming an unbudgeted bill at scale.

These map directly to the review questions in the security section, which is why they save time. The discipline behind them is the work of an AI engineering practice, backed by QA and testing and by DevOps built for healthcare releases.

How Cabot Takes Healthcare AI From Pilot to Production

Each gate in this guide maps to a Cabot practice. Our AI engineering team builds the production system around the model, with evaluation, monitoring and rollback. Our healthcare integration engineers connect it to the EHR and the identity system. Our compliance work prepares the evidence a security review asks for, and our QA and DevOps teams give it the test and release discipline a hospital expects.

That work sits inside a wider healthcare software development practice, so the pilot, the integration and the review evidence come from one engineering team, not three.

Have a pilot that worked and a rollout that has stalled? Talk to Cabot's engineering team.

Conclusion

A healthcare AI pilot to production move is decided by four gates: a security review, an EHR integration, a measure of success and a named owner. The model matters, and it is the part most teams have already solved. In the next 30 days, name the owner, assemble the review packet and agree the stop threshold in writing. Those three steps do more for a stalled pilot than another round of model tuning.